ArticleDermatologic therapy2021
Onset of vitiligo in a psoriasis patient on ixekizumab.
Article in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Bloodletting cupping combined with conventional measures therapy for psoriasis: A systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2023Pooled it
- Liver fibrosis prevalence and risk factors in patients with psoriasis: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Cell-based therapies of autoimmune diseases in the context of artificial intelligence development.Clinical and experimental medicine · 2026Review
- Vitiligo secondary to immunosuppressants: a pharmacovigilance study of the FDA Adverse Event Reporting System.Frontiers in immunology · 2026Article
- Targeted therapies induced depigmentation: a review.Frontiers in immunology · 2025Review
- Ustekinumab is effective in the treatment of linear psoriasis: a case report and literature review.Frontiers in immunology · 2025Review
- Role of Cytokines and Chemokines in Vitiligo and Their Therapeutic Implications.Journal of clinical medicine · 2024Review
- Biologic drugs induced vitiligo: case reports and review of literature.Frontiers in immunology · 2024Review
- Factors Associated with Treatment Satisfaction in Korean Patients with Psoriasis.Patient preference and adherence · 2024Article
- Mechanistic Investigation of WWOX Function in NF-kB-Induced Skin Inflammation in Psoriasis.International journal of molecular sciences · 2023Article
- Guselkumab-induced vitiligo in a patient with psoriatic arthritis.JAAD case reports · 2023Article
- Gasdermin D (GSDMD) Is Upregulated in Psoriatic Skin-A New Potential Link in the Pathogenesis of Psoriasis.International journal of molecular sciences · 2023Article
- New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge.Biomedicines · 2023Review
- Review
- Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center.Biomedicines · 2023Article
- Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?Life (Basel, Switzerland) · 2023Review
- Spontaneous Reversal of Vitiligo, a Rare Phenomenon Reported in a Case in Saudi Arabia with an Insight into Metabolic Biochemical Derangements.Medicina (Kaunas, Lithuania) · 2023Article
- Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19.Tropical medicine and infectious disease · 2023Article
- Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments.Clinical, cosmetic and investigational dermatology · 2023Review
- Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience.Clinical, cosmetic and investigational dermatology · 2023Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVitiligo is an acquired skin disorder clinically characterized by hypopigmentated macules and patches. Psoriasis is a chronic-inflammatory-skin-condition characterized by erythematous-plaques covered with scales particularly over the extensor-surfaces, scalp, and lumbosacral region. Recent major-researches-advancements have significantly expanded our understanding of psoriasis-pathophysiology, resulting in the development of highly effective targeted-therapies, such as anti TNFα, IL-12/23-inhibitors, IL-17-inhibitors, or IL-23-inhibitors. Particularly, ixekizumab, a humanized-monoclonal immunoglobulin-G 4 antibody, specifically binding IL-17A, demonstrated strong efficacy in threating recalcitrant psoriasis. Nevertheless, paradoxical reactions due to IL-17 inhibitors have been described. CASE REPORT: Herein, we report the case of a 53-year-old Caucasian man who obtained complete skin clearance of psoriasis plaques after 16 weeks of ixekizumab treatment together with the appearance of vitiligo patches localized on the facial area. He had never suffered of vitiligo and his family history excluded vitiligo diagnosis. We also could exclude post inflammatory psoriasis hypopigmentation because of absence of facial involvement at baseline. Our experience suggests that vitiligo might be considered a rare adverse effects of anti-IL-17 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.